ClinicalTrials.gg
RecruitingNCT06077201HOMERUNHITTERUpdated Sep 4, 2026

Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions

An interventional study of HBCR hands-off and HBCR interactive in Valvular Heart Disease, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 111 studies in Heart Valve Diseases with a site in United States — 39 open to participants now, 50 under way, none of them phase 3. Heart Valve Diseases · United States.

Planned enrollment
30th of 66
240 · median 207
Started
2023
with 10 others
No phase
55 of 111
15 open now
Primary completion
2027-02
later than 17 of 49 live
Registered
90th of 111
by date

Among the 111 studies in Heart Valve Diseases with a site in United States, this one is the 30th largest by planned enrollment of the 66 interventional ones that give a count, is one of 11 that started in 2023, is one of 55 with no phase, reaches primary completion later than 17 of the 49 other live ones, and was the 90th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

39 of the 111 studies in Heart Valve Diseases with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Heart Valve Diseases with a site in United States, or all of them as a file.
02

Study summary

The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage participation in CBCR are important, many individuals will still not participate for a variety of reasons. This randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients undergoing transcatheter heart valve interventions (THVIs). After a brief roll-in period, participants not intending to participate in CBCR are randomized to one of three groups: (1) control, (2) HBCR mobile health intervention with hands-off delivery, and (3) HBCR mobile health intervention with interactive delivery. Participants in the intervention groups (hands-off/interactive delivery) will also be randomized to continue the intervention for 12 weeks or 24 weeks. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on clinical events, physical activity, quality of life, and other outcomes. Those who intend to participate in CBCR will be followed in a registry.

03

Conditions studied

  • Valvular Heart Disease

Keywords

  • cardiac rehabilitation
  • transcatheter heart valve intervention
  • cardiology
  • aortic stenosis
  • mitral regurgitation
  • tricuspid regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treated with a transcatheter heart valve intervention (e.g., transcatheter aortic valve implantation [in the native valve or valve-in-valve], mitral transcatheter edge-to-edge repair, mitral valve-in-valve) of the aortic, mitral, or tricuspid valve done via transfemoral access

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to provide
  • Not adherent to wearing the ActiGraph activity tracker during the roll-in phase for a minimum of 4 (out of 7) compliant days (worn >10 hours/day)
  • Planned participation in center based cardiac rehabilitation (CBCR)
  • Transcatheter heart valve intervention done via any route other than a transfemoral approach
  • Stroke during or immediately after the transcatheter heart valve intervention prior to randomization
  • Placement of a pacemaker within 6 weeks prior to the transcatheter heart valve intervention or after the transcatheter heart valve intervention and prior to randomization
  • Those who require a walker or who cannot get out of a chair/bed on their own and walk independently (use of a cane is acceptable)
  • Physical or neuropsychiatric limitations that would prevent proficient use of the study tools and successful completion of the physical and quality of life assessments (e.g. blindness, dementia)
  • Planned surgery within 6 months after the heart valve intervention
  • Planned discharge from hospital to hospice, assisted living, or inpatient rehabilitation facility (discharge to a senior facility permitted as long as they are considered Independent Living)
  • Treating provider or site PI indicates that participation in the study would be unsafe
  • Participation in any ongoing randomized trial that has not completed follow-up unless the sponsor of the other trial allows enrollment of the participant in this cardiac rehabilitation trial
  • Unable to complete the baseline study visit prior to 6 weeks after the transcatheter heart valve intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • No intervention
    Control

    Standard of care course for an individual not participating in center based cardiac rehabilitation. AHA Life's Essential 8 Fact Sheets are provided to promote healthy living.

  • Experimental
    HBCR hands-off

    Home-based cardiac rehabilitation with mobile application + AHA Life's Essential 8 sheets.

    Other: HBCR hands-off

  • Experimental
    HBCR interactive

    Home-based cardiac rehabilitation with mobile application and periodic video calls with exercise physiologist + AHA Life's Essential 8 sheets.

    Other: HBCR interactive

Interventions

  • OtherHBCR hands-off

    Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.

  • OtherHBCR interactive

    Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.

06

What researchers measure

Primary outcomes

  1. Probability of the hierarchical clinical event composite

    The hierarchical clinical event composite includes (in order of hierarchy): (1) all-cause death; (2) all-cause hospitalization; and (3) skilled nursing facility visits. To examine whether the intervention improves mortality, hospitalization, and SNF rates after THVIs, we will conduct Bayesian Markov longitudinal proportional odds model on weekly outcome measures. The pooled active treatment vs. control group comparison (primary comparison for the trial) will be estimated by contrasting the average of posterior probability that Y≥y of the two active treatment groups (hands-off HBCR and interactive HBCR) to the control group.

    Time frame: Over the entire available follow-up period for randomized participants (minimum of 6 months, maximum approximately 24-30 months).

  2. Average daily total activity counts

    Daily total activity counts are determined by a triaxial actigraphy device.

    Time frame: The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily total activity counts determined. The primary comparison will be at 12 weeks after randomization.

Secondary outcomes

  1. Average daily total activity counts

    Daily total activity counts are determined by a triaxial actigraphy device.

    Time frame: The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily total activity counts determined. The secondary comparisons will be at 24 and 52 weeks after randomization.

  2. Average daily active minutes

    Daily active minutes are determined by a triaxial actigraphy device.

    Time frame: The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily active minutes determined. The comparisons will be at 12, 24 and 52 weeks after randomization.

  3. Average daily steps

    Daily steps are determined by a triaxial actigraphy device.

    Time frame: The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily steps determined. The comparisons will be at 12, 24 and 52 weeks after randomization.

  4. Average daily energy expenditure

    Daily energy expenditure is determined by a triaxial actigraphy device.

    Time frame: The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily energy expenditure determined. The comparisons will be at 12, 24 and 52 weeks after randomization.

  5. Average daily moderate to vigorous active minutes

    Daily moderate to vigorous active minutes are determined by a triaxial actigraphy device.

    Time frame: The actigraphy device will be worn for approximately one week and, using data from days when the device was worn >10 hours, the average daily moderate to vigorous active mins determined. The comparisons will be at 12, 24 and 52 weeks after randomization.

  6. 6 minute walk distance

    The distance walked in 6 minutes.

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  7. Chair sit to stand time

    The time taken to complete 5 chair rises.

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  8. 5 meter gait speed

    The speed of walking 5 meters (meters/second).

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  9. All-cause hospitalizations

    Hospitalizations for any reason

    Time frame: Over the entire available follow-up period for randomized participants (minimum of 6 months, maximum approximately 24-30 months).

  10. All-cause death

    Death for any cause

    Time frame: Over the entire available follow-up period for randomized participants (minimum of 6 months, maximum approximately 24-30 months).

  11. Heart-failure specific health status assessed by the KCCQ

    Assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ); (score range 0-100, higher is better health status)

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  12. Physical health status assessed by the PROMIS 10

    Global physical health score from the PROMIS 10 Global Health Short Form questionnaire (raw score range 4-20 with corresponding T score and SE, higher is better)

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  13. Mental health status assessed by the PROMIS 10

    Global mental health score from the PROMIS 10 Global Health Short Form questionnaire (raw score range 4-20 with corresponding T score and SE, higher is better)

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  14. Mood disturbance assessed by PHQ9

    Patient health questionnaire 9 (PHQ9); (score range 1-27, higher score worse)

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  15. Patient goals progress score

    A patient goals progress score (-3 to +3) will be determined for 5 domains and the scores combined for a global score from -15 to +15.

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

  16. Basic mobility by AM-PAC

    Basic mobility will be assessed with the Activity Measure for Post-Acute Care (AM-PAC) Basic Mobility Outpatient Short Form (Low Function); (raw score range 0-39 with corresponding T-score and SE, higher score is better)

    Time frame: The comparisons will be at 12, 24 and 52 weeks after randomization.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Feb 2027, 37 months after the start.

Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 37 months is above that.

Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 11, 2023
StartActual
Dec 15, 2023
Primary completionEst.
Feb 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06077201
Responsible party
Brian Lindman (Medical Director, Associate Professor of Medicine, Vanderbilt University Medical Center) — Principal investigator
First posted
Oct 11, 2023
Start date
Dec 15, 2023
Primary completion
Feb 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Anna Vatterott, MPH
Contact
anna.vatterott@vumc.org
615-936-5798
Caleb Hayes, MPH
Contact
caleb.hayes@vumc.org
Brian R. Lindman, MD, MSc
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion